Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 5

BIOMARIN PHARMACEUTICAL INC Form 5 February 12, 2016

February 12	2, 2016										
FORM	15							OMB AF	PROVAL		
			SECURITIES AND EXCHANGE COM				OMMISSION	OMB Number:	3235-0362		
5 obligations may continue.		Wa	Washington, D.C. 20549 FATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Expires:	January 31		
							EFICIAL	Expires: 200 Estimated average burden hours per response 1			
See Instru 1(b). Form 3 F Reported Form 4 Transacti Reported	Filed pur ^{Ioldings} Section 17((a) of the Public U 30(h) of the I	Utility Holdi	ng Comp	bany	Act of	1935 or Section				
1. Name and A Mueller Br	Address of Reporting ian	Symbol BIOM	r Name and Ti ARIN PHA 3MRN]				5. Relationship of I Issuer (Check	Reporting Pers all applicable			
(Last)	(First) ((Month	12/31/2015 below)				XOfficer (give t below)	e title 10% Owner Other (specify below)			
C/O BIOM PHARMA LINDARO	CEUTICAL INC.						VP, Corj	oorate Control	ler		
	(Street)		4. If Amendment, Date Original 6. I Filed(Month/Day/Year)					Individual or Joint/Group Reporting (check applicable line)			
							(check	applicable line)			
SAN RAFA	AEL, CA 949()1					_X_ Form Filed by O Form Filed by M Person				
(City)	(State)	(Zip) Tal	ble I - Non-De	rivative So	ecurit	ies Acqı	uired, Disposed of,	or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		3. Transaction Code (Instr. 8)	(Instr. 3, 4 and 5) Bayes (Instr. 3, 4 and 5) Bayes (A) (Instr. 3, 4 and 5) (Instr. 4 and 5) (In		Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common Stock	10/31/2015 <u>(1)</u>	10/31/2015	А	Amount 127	(D) A	Pric \$ 51.26	12 053	D	Â		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 2270 (9-02)

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 5

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. of D Sø E I S Fi (I
					(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships						
r of the second second	Director	10% Owner	Officer	Other				
Mueller Brian C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL, CA 94901	Â	Â	VP, Corporate Controller	Â				
Signatures								
/s/ Laura Randall Woodhead, Attorney-in-Fact	02/12/2016							
**Signature of Reporting Person	Da	ate						
Explanation of Responses	•							

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents shares acquired by the reporting person on October 31, 2015, pursuant to the issuer's Employee Stock Purchase Plan.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.